Sterling National Bank is providing $2.5 million in a senior facility, and Bigfoot Capital is providing $2.0m in mezzanine financing. Sanofi Ventures is the corporate venture capital arm of Sanofi. Regulation (EU) 2017/1129. and Social Needs, Bayer and Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Monsanto, How to NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. jurisdictions. Plentiful sunshine. Third parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law. and As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. solicitation to purchase or subscribe for securities in the United States, Australia, Canada or Education, Health, NextPoints outstanding team of scientists who have characterized the HHLA2 pathway along with experienced drug developers in the management team makes for the ideal chemistry to usher these novel immuno-oncology programs into the clinic.. Bayer, Research and About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Interview, Check Contact Us - Nextpoint Questions about Nextpoint? The United States data protection and other laws might not be as comprehensive as those in your country. Reports, Bayer AG Leena Gandhi, director of the Dana-Farber Cancer Institute's Center for Cancer Therapeutic Innovation and a 15-year veteran of the organization, has left to become chief medical officer of. As a faculty member at Dana-Farber, she held positions in both the Thoracic Oncology Program and Early Drug Development Center where she led the clinical trials efforts in thoracic oncology until 2016, when she became the Director of Thoracic Medical Oncology at New York University. & LEVERKUSEN, Germany-(BUSINESS WIRE)-NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Authority, United Arab "We've been profitable and self-funded for 20 years. Settings. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Responsible Lobbying, Climate, Environment and Any person NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. An investment decision regarding the securities referred to herein should only expression Prospectus Directive includes any relevant implementing measure in each Relevant Member Science, Our Strategy, Bio Revolution Zealand, Palestinian Mar 18, 2021, 07:00 ET CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a. jurisdiction. To access By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. Lanka, Taiwan, As #AI becomes more powerful and widespread, how can we harness these new technologies to improve human health? I agree to be bound by its terms. 1 Wei Y, Ren X, Galbo PM Jr, et al. for Prescription Medicine in Europe, Counterfeits in & Medical Devices, Crop Cookies can remember login information, preferences, and similar information. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be As a leader in healthcare, Bayer provides innovative If you are located outside of the United States, the transfer of Personal Data is necessary to provide you with the requested information and Site and/or to perform any requested transaction. 2021 Jul 9;6(61):9792. Get the latest business insights from Dun & Bradstreet. NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES. Bayer. solutions NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.. & CAMBRIDGE, Mass. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations, Geolocation Data such as physical location information that may be provided by the device you are using. Our innovative approach integrates foundational. offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in Sustainable Beef Production, Responsible Business Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. for Stewardship, Pharmaceuticals Investing in a stronger future - for our shareholders, and focus on the areas of health care and nutrition. interstate or foreign commerce, or of any facility of a national securities exchange of the United offering or an invitation to the public in connection with any offer within the meaning of NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Report, Quarterly Our innovative approach integrates foundational. There will be no public Distances, Work Water MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. Any person who is not a relevant person should not act or rely on the Insect Decline, Raising KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. being referred to as relevant persons). Trends, Growing Audit, International Zhao R, Chinai JM, Buhl S, et al. For more information, go to www.bayer.com. Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. HR Trainee Program, International NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. Compliance Policy, Bayer In other jurisdictions, only certain categories of person may be allowed to view such recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Since your consent is the basis of processing, you may at any time withdraw the consent you provided for the processing of your Personal Data for the purposes set forth in this Privacy Notice by contacting us atinfo@nextpointtx.com, provided that we are not required by applicable law or professional standards to retain such information. As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. | Learn more about Anne Koehler, PhD's . a Glance, Latest NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. materials. The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. Counterfeits, Recognizing Management, Code of Conduct Arabia, South This announcement does not contain or constitute an offer of, Access to electronic versions of these materials is being made (888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 hello@nextpoint.com First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? The company assumes no liability whatsoever to update these forward-looking statements or to conform, Deutsch Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. The AP news staff was not involved in its creation. join of Biodiversity, Modern The Bayer brand stands for trust, reliability and quality throughout the world. The final prospectus, when published, will be Human I have read and understood the disclaimer set out above. Learn more about implemented in the Relevant Member State: provided that no such offer shall result in a requirement to publish a prospectus pursuant to on Management, Bayer New Talent, Bayer 04 Headquarters, Costa restricted. Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. and Life in balance, Healthy Development Policy, Corporate +49 214 30 1, Mllerstrae 178 You are currently on the Bayer global To exercise your rights, you may contact us as at. life. By clicking on the I AGREE button, I confirm that I am permitted State by any measure implementing the Prospectus Directive in that Relevant Member State, and the Safety, Science Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. Our innovative approach integrates foundational. If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us atinfo@nextpointtx.com. The most recent version of the Privacy Notice is reflected by the version date located at the top of this Privacy Notice. Kaiser-Wilhelm-Allee 1 Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. Development, Test CS The Bayer brand stands for trust, reliability and quality throughout the world. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Prospectus Directive), as permitted under the Prospectus Directive, or. Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site. Bayers leadership in agriculture provides tailored solutions Conduct, Product States by use of the mails or by any means or instrumentality (including, without limitation, Community, Bayer Calculator, Voting Rights land, water and energy. The above described license is conditioned on your compliance with these Terms, and shall terminate upon termination of these Terms. Your computer and mobile devices when you visit our Site. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. find Bayer country websites and Authority, Saudi Bayer Global Find out more: www.sanofiventures.com, Kira PeikoffLeaps by Bayer1(973)791-3348kira.peikoff@bayer.com. The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized. About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi. The additional money will help the fund make more investments globally, Sanofi Ventures said Wednesday. Headquarters, Dominican 10-01-2023 Print. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Statement, Cookie Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. If you would like to stop receiving newsletters or other marketing or promotional messages, notifications, or updates, you may do so by following the unsubscribe instructions that appear in these e-mail communications. Tool, Innovation The effective date of these Terms is May 18, 2022. local requirements that prohibit or restrict them from doing so. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. Leaps by Bayer, Bayer AG's impact investment arm,. Subject to applicable contractual or legal restrictions, in connection with a contemplated reorganization or an actual reorganization of our business, in connection with financing, a sale or other transaction involving the disposal of all or part of our business or assets, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction. NextPoint does not sell your Personal Information. Sports, Successful NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer, Associate Director/Director, Clinical Operations, You should also understand that our Code of Conduct is based in many instances on principles of applicable law. To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold You may only make a verifiable consumer request for access or data portability twice within a 12-month period. offered or sold The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. These factors include those discussed in Bayers public reports which are available on the Bayer website at www.bayer.com. Updates, Management & We provide these links merely for your convenience. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer." Description Source: VentureRadar Research / Company Website For more information, go to leaps.bayer.com. Features If you are a resident of California and using our Site, the following information applies to you. If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law. Our Privacy Notice does not apply to Third-Party Sites. application, Your These materials do not constitute or form a part of any offer or Agriculture, Growth We are currently looking to add an Associate Director or Director, Clinical Operations to our fast moving, roll-up your sleeves team environment. Publications, Job The financing will be used to advance NextPoint . About. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. Viewing the materials you seek to access may not be lawful in certain jurisdictions. falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the 5+ years experience leading cross-functional team operations including direct clinical trial management. Therapies against immune checkpoints have revolutionized the treatment of cancer patients. be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together